secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2022-03-30T23:59:59+00:00
Accession:  0001193125-22-088448
Event type: litigation
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics sued by Janssen over breach of contract, IP ownership
-------------------------------------------------------------------------

- Janssen Biopharma filed complaint in Superior Court of California, San Mateo County on March 26, 2022.
- Alleges breach of contract by CEO Lawrence Blatt and President Leonid Beigelman, tortious interference by Aligos.
- Janssen seeks declaratory judgment on IP ownership, injunctive relief, and monetary damages.
- Company believes allegations are without merit and intends to defend vigorously.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312522088448/0001193125-22-088448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312522088448/d284014d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-088448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer